Literature DB >> 15932714

[Experimental study of pharmaceutic stress myocardial perfusion imaging with higenamine].

Ying-li Zheng1, Rui Shen, Min-fu Yang, De-liang Gu, Li Fang, Zheng Zhang, Zuo-xiang He.   

Abstract

OBJECTIVE: To evaluate the applicative value of higenamine used as a new agent for pharmaceutical stress test in detection of coronary artery disease by radionuclide myocardial perfusion imaging.
METHODS: Thirteen pigs with chronic coronary artery stenosis by placement of the Ameroid constrictor in the middle section of left anterior descending artery were included in this study. Rest, higenamine and dobutamine stress radionuclide myocardial perfusion imaging was performed with Tc-99m-sestamibi.
RESULTS: The sensitivity for detection of coronary artery disease by radionuclide myocardial perfusion imaging was 85% in both higenamine and dobutamine stress imaging. Imaging scores (9.9 +/- 8.5 vs. 9.4 +/- 8.6, P = NS) and defect severity (68% +/- 12% vs. 68% +/- 15%, P = NS) showed no significant difference between higenamine and dobutamine stress test. Agreement of imaging scores between higenamine and dobutamine stress imaging was good (kappa = 0.849, P < 0.0001).
CONCLUSION: Our study demonstrates that detection of coronary artery stenosis and ischemic myocardium by myocardial perfusion imaging with higenamine is highly sensitive.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15932714

Source DB:  PubMed          Journal:  Zhonghua Xin Xue Guan Bing Za Zhi        ISSN: 0253-3758


  2 in total

1.  A phase I study on pharmacokinetics and pharmacodynamics of higenamine in healthy Chinese subjects.

Authors:  Sheng Feng; Ji Jiang; Pei Hu; Jian-yan Zhang; Tao Liu; Qian Zhao; Bi-lu Li
Journal:  Acta Pharmacol Sin       Date:  2012-10-22       Impact factor: 6.150

Review 2.  Role of Higenamine in Heart Diseases: A Mini-Review.

Authors:  Jianxia Wen; Mingjie Li; Wenwen Zhang; Haoyu Wang; Yan Bai; Junjie Hao; Chuan Liu; Ke Deng; Yanling Zhao
Journal:  Front Pharmacol       Date:  2022-01-10       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.